Elenagen + cyclophosphamide + fluorouracil + methotrexate

Elenagen + cyclophosphamide + fluorouracil + methotrexate is an investigational multi-agent regimen combining a novel DNA cancer vaccine (Elenagen) with the established chemotherapeutic protocol known as CMF. - **Elenagen** is a plasmid-based DNA vaccine encoding p62/SQSTM1. It acts via two main mechanisms: stimulating an immune response against p62 (a tumor-associated antigen) and reducing systemic chronic inflammation in the tumor microenvironment[2]. - **Cyclophosphamide**, **methotrexate**, and **fluorouracil** are classic cytotoxic agents used together in the "CMF" regimen for various cancers, including breast cancer. They work by interfering with cell division and nucleic acid synthesis[4][9]. The rationale for this combination is that chemotherapy can reduce immunosuppressive cells within tumors, potentially enhancing the efficacy of immunotherapies like Elenagen. Conversely, Elenagen may modulate inflammation and restore or increase tumor sensitivity to cytotoxic drugs[1][2]. This approach has shown partial responses in heavily pretreated triple-negative breast cancer patients who were resistant to prior lines of therapy[1][7].

Other names

Elenagen plus CMFElenagen with cyclophosphamide/methotrexate/fluorouracil